UIC multi-ethnic dilated cardiomyopathy registry
Official title: University of Illinois Chicago (UIC) Multi-Ethnic Dilated Cardiomyopathy (DCM) Registry
Run by University of Illinois Chicago · NCT07145138 · Data updated 2026-11-12
This project will collect genetic and social data from adults with dilated cardiomyopathy, especially African American and Hispanic/Latino patients, to see if certain genes and social factors explain worse outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | University of Illinois Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | July 11, 2024 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2038 |
| Registry record updated | August 28, 2025 |
| Trial ID | NCT07145138 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults age 18 or older with dilated cardiomyopathy or heart failure who are seen at University of Illinois Hospital and can give written informed consent, especially African American or Hispanic/Latino patients.
✕Probably not a fit
People who are pregnant, incarcerated, minors, unable to consent, or who do not receive care at the study site are unlikely to join or benefit directly from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry enrolls adults with dilated cardiomyopathy seen at the University of Illinois Hospital to collect clinical data, family history, genetic samples, and measures of social and financial stressors. Participants provide written consent and contribute blood or saliva for genetic analysis, complete surveys on social determinants of health, and allow review of their medical records. Investigators will compare the frequency of known and novel genetic variants and the impact of social/medical burdens across racial and ethnic groups. The aim is to determine whether genetic differences and nonmedical stressors help explain higher DCM severity and worse outcomes in minority populations.
Why it matters
Potential benefit: If successful, the findings could improve genetic diagnosis and lead to targeted care strategies that reduce the disproportionate burden of DCM in minority patients.
How similar studies have gone: Genetic studies in predominantly White cohorts have identified several DCM-causing genes, but similar multi-ethnic investigations are limited, so this approach builds on partial prior success but remains under-tested in minority groups.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Must be at least 18 years of age and be admitted to or seen at a UIH site. * Subjects must be willing and able to give written, informed consent Exclusion Criteria: * Adults who are unable to provide consent * Women who are pregnant at the baseline visit, * Prisoners * Individuals who are not yet adults (infants, children, teenagers).
Where it's running
-
University of Illinois Hospital & Health Sciences
Chicago, Illinois, United States Recruiting
Study contacts
- Study coordinator: David Tofovic, M.D.
- Email: dtofov2@uic.edu
- Phone: 312-355-7111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Second infusion of FAP-targeted iCDC for end-stage dilated cardiomyopathy
This study tests whether a second dose of FAP-targeted immunosuppressive CAR-DC therapy can safely improve heart function in adults with end-stage dilated cardiomyopathy who previously had a partial response.
-
Monitoring progression of chronic cardiovascular conditions
This project will collect wearable physiologic data from adults with cardiovascular conditions to see how their heart disease changes over time.
-
Endocardial delivery of stem-cell derived heart cells to help severe heart failure
This study tests endocardial delivery of HS-001 cell sheets made from iPSC-derived cardiomyocytes in adults with severe heart failure and reduced ejection fraction to see if it is safe and may improve heart function over 26 weeks.
-
FAP-targeted immunosuppressive CAR-DC therapy for end-stage dilated cardiomyopathy
Researchers are testing a new immune-cell therapy to see if it’s safe and helps people with end-stage dilated cardiomyopathy.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.